Residual Inflammation Increases Heart Attack Risk

New study finds persistent inflammation boosts cardiovascular event rates despite controlled traditional risk factors.

Updated on Oct. 29, 2026 in Heart Disease

Isometric editorial illustration of a stylized heart valve and cellular structures, representing cardiovascular medical research findings. — A study of 3,887 patients reveals that residual inflammation is a significant driver of cardiovascular events, regardless of traditional risk factors. AI Illustration. Upload story photo >

Live Poll

Should doctors test for inflammation levels to better manage heart health after a surgery?

A study of 3887 patients shows that residual inflammatory risk significantly raises the likelihood of major adverse cardiovascular events after heart surgery. Patients with elevated inflammation levels faced a higher risk of mortality even when traditional factors like cholesterol and blood pressure were controlled.

Why it matters

The findings highlight the importance of targeting inflammation beyond traditional risk factors to improve long-term outcomes for heart patients. This suggests that current management strategies may leave a portion of patients vulnerable to severe complications.

Researchers identified a 58% higher adjusted risk for major adverse cardiovascular events and a 78% higher adjusted risk for mortality among patients with residual inflammatory risk. These figures were drawn from a study of 3887 patients.

The players

Heart

This is a peer-reviewed medical journal that publishes original research and clinical studies related to cardiovascular medicine.

The details

Researchers found that 1258 patients exhibited residual inflammatory risk, defined as high-sensitivity C-reactive protein levels of 2 mg/L or higher. While major adverse cardiovascular event rates were similar between groups during the first 30 days, differences became apparent over one year.

The study cohort underwent percutaneous coronary intervention between January 2012 and December 2023.
The research findings were published in the journal Heart on October 21, 2026.

The Big Picture

This study follows the precedent set by the CANTOS trial's anti-inflammatory therapy findings by confirming that inflammation remains a critical therapeutic target in cardiology. It updates the understanding of long-term outcomes for patients who have already achieved control over traditional risk factors.

Patients with a history of heart intervention should discuss the significance of inflammation markers with their medical providers. This evidence suggests that reaching blood pressure and cholesterol targets may not be sufficient for all patients to avoid adverse outcomes.

The takeaway

Patients who have undergone cardiac intervention should work with their doctors to evaluate inflammatory markers alongside traditional cholesterol and blood pressure metrics. This proactive approach may help identify individuals who remain at elevated risk despite standard medical care.